{"id":845888,"date":"2025-05-02T07:04:51","date_gmt":"2025-05-02T11:04:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/"},"modified":"2025-05-02T07:04:51","modified_gmt":"2025-05-02T11:04:51","slug":"breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/","title":{"rendered":"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma"},"content":{"rendered":"<p>        <!--.bwalignr { text-align: right; list-style-position: inside }\n.bwlistcircle { list-style-type: circle }\n.bwlistdecimal { list-style-type: decimal }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma<\/b><\/p>\n<p>WILMINGTON, Del.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nPositive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca\u2019s fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide\/glycopyrronium\/formoterol fumarate or BGF (320\/28.8\/9.6\u03bcg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid\/long-acting beta2-agonist (ICS\/LABA) medicines.\n<\/p>\n<p>\nKALOS and LOGOS were replicate, randomized, double-blind trials designed to investigate BREZTRI<i \/>as a potential treatment for asthma.<sup>1,2 <\/sup>The trials evaluated the efficacy and safety of BREZTRI<i \/>versus maintenance treatment with ICS\/LABA in adults and adolescents with uncontrolled asthma.<sup>1,2<\/sup><\/p>\n<p>\nAsthma is a common, chronic respiratory disease characterized by inflammation and muscle tightening in the airway (bronchoconstriction), which can make it difficult to breathe.<sup>3<\/sup> As many as 262 million people worldwide are affected by asthma,<sup>3<\/sup> and it is estimated that nearly half of those treated with dual therapy remain uncontrolled, which can significantly limit lung function and decrease quality of life.<sup>4,5<\/sup><\/p>\n<p>\nAlberto Papi, Professor and Chair of Respiratory Medicine at the University of Ferrara, and Director of the Respiratory Unit, CardioRespiratory Department, S. Anna University Hospital, Ferrara, Italy, and primary investigator, said: \u201cDespite advancements in asthma treatments, millions of patients remain uncontrolled, which can cause frequent breathlessness, coughing and wheezing, significantly impacting their ability to perform daily activities. The results from the KALOS and LOGOS trials are exciting and demonstrate the potential of budesonide\/glycopyrronium\/formoterol to evolve the standard of care to more effectively treat asthma in a single inhaled triple therapy for patients who remain uncontrolled with dual maintenance therapy.\u201d\n<\/p>\n<p>\nSharon Barr, Executive Vice President, BioPharmaceuticals R&amp;D, AstraZeneca, said: \u201cWe are excited by the positive results from the KALOS and LOGOS trials, which demonstrate that BREZTRI could help improve the lives of the millions of patients living with asthma. These asthma data build on the well-established profile of BREZTRI in COPD, and we look forward to sharing with regulatory authorities to bring this important medicine to a wider group of patients.\u201d\n<\/p>\n<p>\nThere were no new safety or tolerability signals identified for BREZTRI in KALOS or LOGOS.\n<\/p>\n<p>\nFull results from the two Phase III trials will be shared with regulatory authorities and presented at an upcoming medical meeting.\n<\/p>\n<p>\nBREZTRI is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease (COPD) in adults in more than 80 countries worldwide including the US, EU, China and Japan.\n<\/p>\n<p><b>IMPORTANT SAFETY INFORMATION<\/b><\/p>\n<p><b>BREZTRI AEROSPHERE<sup>\u00ae<\/sup> (budesonide, glycopyrrolate, and formoterol fumarate) Inhalation Aerosol<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nBREZTRI is contraindicated in patients who have a hypersensitivity to budesonide, glycopyrrolate, formoterol fumarate, or product excipients\n<\/li>\n<li>\nBREZTRI is not indicated for treatment of asthma. Long-acting beta2-adrenergic agonist (LABA) monotherapy for asthma is associated with an increased risk of asthma-related death. These findings are considered a class effect of LABA monotherapy. When a LABA is used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone. Available data do not suggest an increased risk of death with use of LABA in patients with COPD\n<\/li>\n<li>\nBREZTRI should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition\n<\/li>\n<li>\nBREZTRI is NOT a rescue inhaler. Do NOT use to relieve acute symptoms; treat with an inhaled short-acting beta2-agonist\n<\/li>\n<li>\nBREZTRI should not be used more often than recommended; at higher doses than recommended; or in combination with LABA-containing medicines, due to risk of overdose. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs\n<\/li>\n<li>\nOropharyngeal candidiasis has occurred in patients treated with orally inhaled drug products containing budesonide. Advise patients to rinse their mouths with water without swallowing after inhalation\n<\/li>\n<li>\nLower respiratory tract infections, including pneumonia, have been reported following ICS. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of pneumonia and exacerbations frequently overlap\n<\/li>\n<li>\nDue to possible immunosuppression, potential worsening of infections could occur. Use with caution. A more serious or fatal course of chickenpox or measles can occur in susceptible patients\n<\/li>\n<li>\nParticular care is needed for patients transferred from systemic corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients during and after transfer. Taper patients slowly from systemic corticosteroids if transferring to BREZTRI\n<\/li>\n<li>\nHypercorticism and adrenal suppression may occur with regular or very high dosage in susceptible individuals. If such changes occur, consider appropriate therapy\n<\/li>\n<li>\nCaution should be exercised when considering the coadministration of BREZTRI with long-term ketoconazole and other known strong CYP3A4 Inhibitors. Adverse effects related to increased systemic exposure to budesonide may occur\n<\/li>\n<li>\nIf paradoxical bronchospasm occurs, discontinue BREZTRI immediately and institute alternative therapy\n<\/li>\n<li>\nAnaphylaxis and other hypersensitivity reactions (eg, angioedema, urticaria or rash) have been reported. Discontinue and consider alternative therapy\n<\/li>\n<li>\nUse caution in patients with cardiovascular disorders, especially coronary insufficiency, as formoterol fumarate can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles\n<\/li>\n<li>\nDecreases in bone mineral density have been observed with long-term administration of ICS. Assess initially and periodically thereafter in patients at high risk for decreased bone mineral content\n<\/li>\n<li>\nGlaucoma and cataracts may occur with long-term use of ICS. Worsening of narrow-angle glaucoma may occur, so use with caution. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use BREZTRI long term. Instruct patients to contact a healthcare provider immediately if symptoms occur\n<\/li>\n<li>\nWorsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to contact a healthcare provider immediately if symptoms occur\n<\/li>\n<li>\nUse caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis or unusually responsive to sympathomimetic amines\n<\/li>\n<li>\nBe alert to hypokalemia or hyperglycemia\n<\/li>\n<li>\nMost common adverse reactions in a 52-week trial (incidence \u2265 2%) were upper respiratory tract infection (5.7%), pneumonia (4.6%), back pain (3.1%), oral candidiasis (3.0%), influenza (2.9%), muscle spasms (2.8%), urinary tract infection (2.7%), cough (2.7%), sinusitis (2.6%), and diarrhea (2.1%). In a 24-week trial, adverse reactions (incidence \u2265 2%) were dysphonia (3.3%) and muscle spasms (3.3%)\n<\/li>\n<li>\nBREZTRI should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors and tricyclic antidepressants, as these may potentiate the effect of formoterol fumarate on the cardiovascular system\n<\/li>\n<li>\nBREZTRI should be administered with caution to patients being treated with:<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nStrong cytochrome P450 3A4 inhibitors (may cause systemic corticosteroid effects)\n<\/li>\n<li>\nAdrenergic drugs (may potentiate effects of formoterol fumarate)\n<\/li>\n<li>\nXanthine derivatives, steroids, or non-potassium sparing diuretics (may potentiate hypokalemia and\/or ECG changes)\n<\/li>\n<li>\nBeta-blockers (may block bronchodilatory effects of beta-agonists and produce severe bronchospasm)\n<\/li>\n<li>\nAnticholinergic-containing drugs (may interact additively). Avoid use with BREZTRI\n<\/li>\n<\/ul>\n<\/li>\n<li>\nUse BREZTRI with caution in patients with hepatic impairment, as budesonide and formoterol fumarate systemic exposure may increase. Patients with severe hepatic disease should be closely monitored\n<\/li>\n<\/ul>\n<p><b>INDICATION<\/b><\/p>\n<p>\nBREZTRI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).\n<\/p>\n<p><b>LIMITATIONS OF USE<\/b><\/p>\n<p>\nNot indicated for the relief of acute bronchospasm or for the treatment of asthma.\n<\/p>\n<p><b>Please see full BREZTRI <\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.azpicentral.com%2Fpi.html%3Fproduct%3Dbreztri&amp;esheet=54247853&amp;newsitemid=20250502498123&amp;lan=en-US&amp;anchor=Prescribing+Information&amp;index=1&amp;md5=38952f6fe8b0a779d5eee19b46e2630f\"><b>Prescribing Information<\/b><\/a>,<b> including <\/b><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.azpicentral.com%2Fpi.html%3Fproduct%3Dbreztri%26medguide%3Dy&amp;esheet=54247853&amp;newsitemid=20250502498123&amp;lan=en-US&amp;anchor=Patient+Information&amp;index=2&amp;md5=68e85037c82e4d2c650595a75fcf2b38\"><b>Patient Information<\/b><\/a><b>.<\/b><\/p>\n<p><i>You may<b \/><\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fus-aereporting.astrazeneca.com%2F&amp;esheet=54247853&amp;newsitemid=20250502498123&amp;lan=en-US&amp;anchor=report+side+effects+related+to+AstraZeneca+products&amp;index=3&amp;md5=cd841a94c984a6f159725915b01d4aea\"><i>report side effects related to AstraZeneca products<\/i><\/a>.\n<\/p>\n<p><b>Notes<\/b><\/p>\n<p><b>Asthma<\/b><\/p>\n<p>\nAsthma is a prevalent, chronic respiratory disease affecting as many as 262 million people worldwide,<sup>3 <\/sup>including over 25 million in the US.<sup>6<\/sup> When uncontrolled, inflammation and muscle tightening in the airway (bronchoconstriction) may cause wheezing, breathlessness, chest tightness, coughing, and even death.<sup>3,7<\/sup> Many patients remain uncontrolled despite the availability of standard of care medicines and continue to experience significant limitations on lung function and reduced quality of life.<sup>4,5<\/sup><\/p>\n<p><b>KALOS and LOGOS Phase III trials<\/b><\/p>\n<p>\nKALOS and LOGOS are replicate confirmatory, randomized, double-blind, double-dummy, parallel group, multi-centre, 24-to-52-week variable length Phase III trials to assess the efficacy and safety of BGF (320\/28.8\/9.6\u03bcg and 320\/14.4\/9.6\u03bcg) compared with two fixed-dose, dual-combination therapies of budesonide, an ICS, and formoterol fumarate, a LABA: PT009 (in an<i \/>AEROSPHERE<i \/>inhaler) and SYMBICORT pressurized metered-dose inhaler (pMDI).<sup>1,2 <\/sup>KALOS and LOGOS included approximately 4,400 randomized patients.\n<\/p>\n<p>\nThe trial design was optimized to evaluate the 320\/28.8\/9.6\u03bcg dose of BGF. The primary efficacy endpoints for the two individual trials were a change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 24 and trough FEV1 over 12-24 weeks and over 24 weeks.<sup>1,2<\/sup><\/p>\n<p>\nIn addition to the two registrational trials, KALOS and LOGOS,<sup \/>two qualifying trials, LITHOS and VATHOS,<sup>8,9 <\/sup>also met their primary endpoints. LITHOS and VATHOS included approximately 1,000 randomized patients.\n<\/p>\n<p><b>AstraZeneca in Respiratory &amp; Immunology<\/b><\/p>\n<p>\nRespiratory &amp; Immunology, part of AstraZeneca BioPharmaceuticals is a key disease area and growth driver to the Company.\n<\/p>\n<p>\nAstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The Company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. Our ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases.\n<\/p>\n<p><b>AstraZeneca<\/b><\/p>\n<p>\nAstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal &amp; Metabolism, and Respiratory &amp; Immunology. Based in Cambridge, UK, AstraZeneca operates in over 125 countries, and its innovative medicines are used by millions of patients worldwide. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fnam05.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Fwww.astrazeneca-us.com%252F%26data%3D02%257C01%257CJulia.Drabick%2540edelman.com%257C5e1836e411194a4a386408d84e890886%257Cb824bfb3918e43c2bb1cdcc1ba40a82b%257C0%257C0%257C637345697783430188%26sdata%3DlXKaI11uYzlIBvV6fwXLVhr7oZDfC048ruLXLReanJg%253D%26reserved%3D0&amp;esheet=54247853&amp;newsitemid=20250502498123&amp;lan=en-US&amp;anchor=www.astrazeneca-us.com&amp;index=4&amp;md5=3bb8daa08ec1187ce49044c1c8aa183c\">www.astrazeneca-us.com<\/a> and follow us on social media <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fastrazeneca%2F&amp;esheet=54247853&amp;newsitemid=20250502498123&amp;lan=en-US&amp;anchor=%40AstraZeneca&amp;index=5&amp;md5=7ee6535fb9bca858e4fe4998b5266449\">@AstraZeneca<\/a>.\n<\/p>\n<p><b>References<\/b><\/p>\n<ol class=\"bwlistdecimal\">\n<li>\nClinicaltrials.gov. Study to Assess PT010 in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS) [Online]. Available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04609878%3Flimit%3D25%26term%3DKALOS%26rank%3D1&amp;esheet=54247853&amp;newsitemid=20250502498123&amp;lan=en-US&amp;anchor=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04609878%3Flimit%3D25%26amp%3Bterm%3DKALOS%26amp%3Brank%3D1&amp;index=6&amp;md5=c3e8536d4df89205009c75e5e3c95c1a\">https:\/\/clinicaltrials.gov\/study\/NCT04609878?limit=25&amp;term=KALOS&amp;rank=1<\/a>. [Last accessed: May 2025].\n<\/li>\n<li>\nClinicaltrials.gov. Study to Assess PT010 in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS) [Online]. Available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04609904%3Flimit%3D25%26term%3DLOGOS%26rank%3D4&amp;esheet=54247853&amp;newsitemid=20250502498123&amp;lan=en-US&amp;anchor=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT04609904%3Flimit%3D25%26amp%3Bterm%3DLOGOS%26amp%3Brank%3D4&amp;index=7&amp;md5=faa73dc7ffee4ac5acb298da75dd3e17\">https:\/\/clinicaltrials.gov\/study\/NCT04609904?limit=25&amp;term=LOGOS&amp;rank=4<\/a>. [Last accessed: May 2025].\n<\/li>\n<li>\nGlobal Asthma Network. The Global Asthma Report 2022. [Online]. Available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fglobalasthmareport.org%2Fresources%2FGlobal_Asthma_Report_2022.pdf&amp;esheet=54247853&amp;newsitemid=20250502498123&amp;lan=en-US&amp;anchor=http%3A%2F%2Fglobalasthmareport.org%2Fresources%2FGlobal_Asthma_Report_2022.pdf&amp;index=8&amp;md5=a46ac70a0db7ec5a0e2e57de75620511\">http:\/\/globalasthmareport.org\/resources\/Global_Asthma_Report_2022.pdf<\/a>. [Last accessed: May 2025].\n<\/li>\n<li>\nDavis J, <i>et al<\/i>. Burden of asthma among patients adherent to ICS\/LABA: A real-world study. <i>J Asthma<\/i>. 2019 Mar;56(3):332-340.\n<\/li>\n<li>\nBuhl R, <i>et al<\/i>. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting \u03b22-agonist in UK primary care settings. <i>Respir Med<\/i>. 2020 Feb: 162:105859.\n<\/li>\n<li>\nU.S. Centers for Disease Control and Prevention (CDC). Most Recent National Asthma Data. [Online]. Available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.cdc.gov%2Fasthma%2Fmost_recent_national_asthma_data.htm&amp;esheet=54247853&amp;newsitemid=20250502498123&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.cdc.gov%2Fasthma%2Fmost_recent_national_asthma_data.htm&amp;index=9&amp;md5=c09369a044e2dbc02f4f7dcd3cb17438\">https:\/\/www.cdc.gov\/asthma\/most_recent_national_asthma_data.htm<\/a>. [Last accessed: May 2025].\n<\/li>\n<li>\nFernandes AG, <i>et al<\/i>. Risk factors for death in patients with severe asthma. <i>J Bras Pneumol<\/i>. 2014; 40 (4): 364-372.\n<\/li>\n<li>\nClinicaltrials.gov. A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma (LITHOS) [Online]. Available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05755906%3Flimit%3D25%26term%3DLITHOS%26rank%3D1&amp;esheet=54247853&amp;newsitemid=20250502498123&amp;lan=en-US&amp;anchor=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05755906%3Flimit%3D25%26amp%3Bterm%3DLITHOS%26amp%3Brank%3D1&amp;index=10&amp;md5=13b213e363479892f88baee6acd16454\">https:\/\/clinicaltrials.gov\/study\/NCT05755906?limit=25&amp;term=LITHOS&amp;rank=1<\/a>. [Last Accessed: May 2025].\n<\/li>\n<li>\nClinicaltrials.gov. A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants with Inadequately Controlled Asthma (VATHOS) [Online]. Available at: <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05202262%3Flimit%3D25%26term%3DVATHOS%26rank%3D1&amp;esheet=54247853&amp;newsitemid=20250502498123&amp;lan=en-US&amp;anchor=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05202262%3Flimit%3D25%26amp%3Bterm%3DVATHOS%26amp%3Brank%3D1&amp;index=11&amp;md5=10033906207b461db77a043ec03052a9\">https:\/\/clinicaltrials.gov\/study\/NCT05202262?limit=25&amp;term=VATHOS&amp;rank=1<\/a>. [Last Accessed: May 2025].\n<\/li>\n<li>\nAstraZeneca Data on File. 2025. REF-270910.\n<\/li>\n<\/ol>\n<p class=\"bwalignr\">\nLast Updated 4\/2025\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250502498123r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250502498123\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250502498123\/en\/<\/a><\/span><\/p>\n<p><b>Media Inquiries<br \/>\n<\/b><br \/>Fiona Cookson +1 212 814 3923<br \/>\n<br \/>Jillian Gonzales +1 302 885 2677\n<\/p>\n<p>\nUS Media Mailbox: <a rel=\"nofollow\" href=\"mailto:usmediateam@astrazeneca.com\">usmediateam@astrazeneca.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Delaware<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology General Health Health Pharmaceutical Clinical Trials<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20250502498123\/en\/2456877\/3\/AZ_CMYK_H_COL.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma WILMINGTON, Del.&#8211;(BUSINESS WIRE)&#8211; Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca\u2019s fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide\/glycopyrronium\/formoterol fumarate or BGF (320\/28.8\/9.6\u03bcg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid\/long-acting beta2-agonist (ICS\/LABA) medicines. KALOS and LOGOS were replicate, randomized, double-blind trials designed to investigate BREZTRIas a potential treatment for asthma.1,2 The trials evaluated the efficacy and safety of BREZTRIversus maintenance treatment with ICS\/LABA in adults and adolescents with uncontrolled asthma.1,2 Asthma is a common, chronic respiratory disease characterized by inflammation and muscle tightening in the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-845888","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma WILMINGTON, Del.&#8211;(BUSINESS WIRE)&#8211; Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca\u2019s fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide\/glycopyrronium\/formoterol fumarate or BGF (320\/28.8\/9.6\u03bcg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid\/long-acting beta2-agonist (ICS\/LABA) medicines. KALOS and LOGOS were replicate, randomized, double-blind trials designed to investigate BREZTRIas a potential treatment for asthma.1,2 The trials evaluated the efficacy and safety of BREZTRIversus maintenance treatment with ICS\/LABA in adults and adolescents with uncontrolled asthma.1,2 Asthma is a common, chronic respiratory disease characterized by inflammation and muscle tightening in the &hellip; Continue reading &quot;BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-02T11:04:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250502498123r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma\",\"datePublished\":\"2025-05-02T11:04:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\\\/\"},\"wordCount\":1934,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250502498123r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\\\/\",\"name\":\"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250502498123r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-05-02T11:04:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250502498123r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250502498123r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/","og_locale":"en_US","og_type":"article","og_title":"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma - Market Newsdesk","og_description":"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma WILMINGTON, Del.&#8211;(BUSINESS WIRE)&#8211; Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca\u2019s fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide\/glycopyrronium\/formoterol fumarate or BGF (320\/28.8\/9.6\u03bcg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid\/long-acting beta2-agonist (ICS\/LABA) medicines. KALOS and LOGOS were replicate, randomized, double-blind trials designed to investigate BREZTRIas a potential treatment for asthma.1,2 The trials evaluated the efficacy and safety of BREZTRIversus maintenance treatment with ICS\/LABA in adults and adolescents with uncontrolled asthma.1,2 Asthma is a common, chronic respiratory disease characterized by inflammation and muscle tightening in the &hellip; Continue reading \"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-02T11:04:51+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250502498123r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma","datePublished":"2025-05-02T11:04:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/"},"wordCount":1934,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250502498123r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/","name":"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250502498123r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-05-02T11:04:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250502498123r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250502498123r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/breztri-met-primary-endpoints-in-kalos-and-logos-phase-iii-trials-in-asthma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/845888","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=845888"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/845888\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=845888"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=845888"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=845888"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}